ToPCaP

About

About the collaboration

An epidemiologist at the Harvard School of Public Health and a pathologist at Dana Farber Cancer Institute came to the conclusion that the important scientific questions relating to prostate cancer could not be found in either the molecular pathology lab or in epidemiology population studies alone. To address this shortcoming, in 2008 they created the novel team now known as ToPCaP (Transdisciplinary Prostate Cancer Partnership), which integrates molecular pathology and large-scale epidemiological studies. This combined effort allows ToPCaP to effectively address the pressing prostate cancer questions of the day. This forward-thinking synergistic pairing of pathology and epidemiology provides opportunities for translational research - research that can be generated in a lab and applied in the clinic. Since its inception in 2008, ToPCaP has grown into an international consortium of researchers from diverse cross-functional fields, including epidemiology, molecular pathology, clinical oncology, genetics, biostatistics, and basic science. ToPCaP's goal is to decrease the morbidity and mortality of prostate cancer patients through groundbreaking research.

About the steering committee
The steering committee is made up of one researcher from each institution, and helps to lead the scientific agenda and priorities for the group.


Ove Andrén
Associate Professor of Urology
Örebro University

Stephen Finn
Associate Professor of Pathology
Trinity College, Dublin

Michelangelo Fiorentino
Lead Pathologist
S. Orsola-Malpighi Hospital

Mieke Van Hemelrijck
Senior Lecturer in Cancer Epidemiology
King's Health Partners

Massimo Loda
Professor of Pathology
Dana Farber Cancer Institute

Lorelei Mucci
Associate Professor of Epidemiology
Harvard T.H. Chan School of Public Health

Unnur Valdimarsdóttir
Professor of Epidemiology
University of Iceland

Mission Statement

Our mission is to characterize the key molecular and phenotypic pathways important in prostate cancer development and progression in order to improve the health of prostate cancer patients through informed treatment and prevention strategies. To accomplish this goal, we seek to identify the key biological markers that can be implemented clinically to refine prostate cancer treatment decisions and to define biomarkers of susceptibility, prediction, and prognosis to impact men's health. We address this goal through an international, multi-discipline consortium of prostate cancer researchers and clinicians with access to unique biobanks of prostate cancer populations from the US and across Europe. We believe the synergy created by combining the population science perspective of epidemiology and biostatistics with molecular pathology, genetics and oncologic clinical expertise will allow us to answer fundamentally important questions about prostate cancer.